Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 30 entities : Eli lilly and company save search
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Published: 2021-09-30 (Crawled : 10:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.1%
H: 1.7%
C: 0.06%
hair regrowth growth phase 3
Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study
Published: 2021-09-30 (Crawled : 10:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
diabetes insulin tirzepatide
Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
Published: 2021-09-30 (Crawled : 10:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
diabetes insulin liver tirzepatide
Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption
Published: 2021-09-30 (Crawled : 06:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
results
Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors
Published: 2021-09-30 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.1%
H: 1.7%
C: 0.06%
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor
Published: 2021-09-30 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.